Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

[1]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Mackey,et al.  BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy , 2010, Clinical Cancer Research.

[3]  C. Caldas,et al.  Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). , 2010, The Lancet. Oncology.

[4]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[5]  E. Perez,et al.  Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Piccart-Gebhart,et al.  Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer , 2010, Nature Reviews Clinical Oncology.

[7]  E. Álava,et al.  Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer , 2010, Breast Cancer Research and Treatment.

[8]  E. Perez,et al.  Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization , 2010, Breast Cancer Research and Treatment.

[9]  Lajos Pusztai,et al.  Gene expression profiling of breast cancer , 2009, Breast Cancer Research.

[10]  D. Hayes.  Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? , 2009, Breast.

[11]  W. Weichert,et al.  Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy , 2009, Breast Cancer Research.

[12]  F. Penault-Llorca,et al.  Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Baselga,et al.  Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[15]  I. Ellis,et al.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.

[16]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Holmes,et al.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Bao.  Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197 , 2009 .

[19]  Vassilis Georgoulias,et al.  FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG) , 2009, Breast Cancer Research and Treatment.

[20]  A. Giobbie-Hurder,et al.  Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[22]  Arrate Plazaola,et al.  Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. , 2008, Journal of the National Cancer Institute.

[23]  G. Hortobagyi,et al.  Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Harbeck,et al.  Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1–3 positive lymph nodes , 2008 .

[25]  M. Costantini,et al.  Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group , 2008 .

[26]  R. Gelber,et al.  Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. , 2008, Journal of the National Cancer Institute.

[27]  S. Rosenberg.  Follicular lymphoma revisited. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Gelber,et al.  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.

[29]  F. Cognetti,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2008, The New England journal of medicine.

[30]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Andreas Makris,et al.  Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients , 2008, Breast Cancer Research and Treatment.

[32]  D. Ghersi,et al.  Taxanes for adjuvant treatment of early breast cancer. , 2007, The Cochrane database of systematic reviews.

[33]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[34]  C. Sotiriou,et al.  Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer , 2007, Clinical Cancer Research.

[35]  T. Delozier,et al.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Noguchi.  Predictive factors for response to docetaxel in human breast cancers , 2006, Cancer science.

[37]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Lluch,et al.  Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  M. Milella,et al.  Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.

[40]  Donald A. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .

[41]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[42]  M. Dimopoulos,et al.  Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapy , 2006, Breast Cancer Research and Treatment.

[43]  U. Dafni,et al.  Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Ahluwalia,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[46]  J. Bryant,et al.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[48]  H. Earl,et al.  Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Daniel Birnbaum,et al.  Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. , 2005, Cancer research.

[50]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Antón,et al.  Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  Terry L. Smith,et al.  Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Bonetti,et al.  A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. , 2000, Statistics in medicine.

[55]  J. Bergh,et al.  Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[57]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.